Table 1.
Demographic and clinical characteristics of 44 patients with multiple myeloma, stratified by anti-SARS-CoV-2 RBD antibody response to two-dose SARS-CoV-2 mRNA vaccination
| Overall (n = 44) | Detectable antibodya (n = 41) | Undetectable antibodya (n = 3) | |
|---|---|---|---|
| Age, median (IQR) | 64 (57, 69) | 64 (57, 69) | 58 (55, 58) |
| Female, no. (%) | 30 (68) | 28 (93) | 2 (7) |
| Non-white, no. (%) | 1 (2) | 1 (100) | 0 (0) |
| Vaccine manufacturer, no. (%) | |||
| Pfizer/BioNTech | 22 (50) | 21 (95) | 1 (5) |
| Moderna | 22 (50) | 20 (91) | 2 (9) |
| Days from vaccine to antibody testing, median (IQR) | 29 (28, 32) | 29 (27, 31) | 32 (28, 38) |
| Therapy, no. (%) | |||
| Not on therapy | 17 (39) | 16 (94) | 1 (6) |
| On therapyb | 27 (61) | 25 (93) | 2 (7) |
| Bortezomib | 1 (2) | 1 (100) | 0 (0) |
| Carfilzomib | 1 (2) | 1 (100) | 0 (0) |
| Daratumumab | 7 (16) | 7 (100) | 0 (0) |
| Ixazomib | 2 (5) | 1 (50) | 1 (50) |
| Lenalidomide | 17 (39) | 16 (94) | 1 (6) |
| Pomalidomide | 4 (9) | 4 (100) | 0 (0) |
| Teclistamab | 1 (2) | 0 (0) | 1 (100) |
a The percentages in these columns are shown as percent of each category in the overall column. Detectable antibody is defined as an anti-SARS-CoV-2 RBD antibody titer > 0.79 U/mL by the manufacturer
b Since participants could report more than one therapy, the sum of the therapies is greater than the total N